Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Kraft Heinz reported for 6 months of 2023

8/2/23 KHC

G1 Therapeutics reported for 6 months of 2023

8/2/23 GTHX

CVS Health reported for 6 months 2023

8/2/23 CVS

Container ship Sankt Peterburg joined the Fesco fleet

8/2/23 FESH

The Electronic Arts announced a quarterly dividend

8/2/23 EA

The General Dynamics announced a quarterly dividend

8/2/23 GD

Victoria chain may cost X5 Retail Group ₽9 billion

8/2/23 -

SolarEdge reported for 6 months of 2023

8/2/23 SEDG

Virgin Galactic has reported 6 months of 2023.

8/2/23 SPCE

AMD reported for 6 months of 2023

8/2/23 AMD